Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05688306

To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment

Chemotherapy-induced Thrombocytopenia Clinical Trial

Official title:
A Real World Observational Study to Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Platelet-raising Therapy

Clinical Trial Summary

Chemotherapy-induced thrombocytopenia (CIT) is a common hematological toxicity in patients with solid tumors undergo chemotherapy, which can increase the risk of bleeding, prolong hospital stay, increase medical costs, and even lead to death in severe cases. The incidence and severity of CIT varies among different chemotherapy regimens. Recombinant human interleukin-11 (rhIL-11) and recombinant human thrombopoietin (rhTPO) have been approved for the treatment of chemotherapy-induced thrombocytopenia. Tumor patients are at high risk for venous thromboembolism (VTE). In the clinical study of rhIL-11, it was found that the administration of rhIL-11 in healthy subjects caused an increase in the plasma concentration of vWF factor in the form of normal mults. The application of rhIL-11 in patients with myeloid leukemia can increase the concentration of α2 globulin, fibrinogen and prothrombin time. However, there have been no large-scale clinical studies at home and abroad to evaluate whether platelet raising therapy will increase the risk of thrombosis in chemotherapy patients with solid tumor. This study is aimed to evaluate the efficacy and safety of platelet upwelling therapy in patients with solid tumors undergoing chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05688306
Study type Observational
Source Liaoning Tumor Hospital & Institute
Contact
Status Completed
Phase
Start date September 2, 2020
Completion date May 16, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05969158 - Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma Phase 2
Active, not recruiting NCT03362177 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer Phase 3
Recruiting NCT05554913 - Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia Phase 2/Phase 3
Completed NCT00283439 - A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma Phase 1/Phase 2
Not yet recruiting NCT06099925 - The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies Phase 2
Completed NCT03471078 - Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers Phase 3
Active, not recruiting NCT03976882 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. Phase 3
Recruiting NCT05772546 - Avatrombopag vs. Placebo for CIT in GI Malignancies Phase 2
Not yet recruiting NCT05864014 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. Phase 3
Terminated NCT01345214 - A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia Phase 1
Completed NCT01663441 - A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 Phase 3
Recruiting NCT05236582 - Herombopag for Chemotherapy-induced Thrombocytopenia Phase 2
Not yet recruiting NCT05944211 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia Phase 2
Withdrawn NCT03343847 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. Phase 3
Completed NCT05851027 - Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia Phase 2/Phase 3
Not yet recruiting NCT03049774 - A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor N/A
Recruiting NCT03937154 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer Phase 3
Recruiting NCT05218226 - Avatrombopag for Chemotherapy-induced Thrombocytopenia Phase 2
Recruiting NCT04600960 - Eltrombopag for Chemotherapy-induced Thrombocytopenia Phase 2
Completed NCT00413283 - Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) Phase 2